adnews Message Board - Msg: 14393415

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : adnews

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: KevRupert who started this subject	9/15/2000 4:00:17 PM
From: KevRupert	of 252

Breaking IVX News (Stock Halted): IVX: Ivax Gets FDA Approval for Cancer Drug By David A. Gaffen Staff Reporter 9/15/00 2:55 PM ET URL: thestreet.com Ivax (IVX:AMEX) has received final approval from the Food and Drug Administration to sell a generic version of the cancer treating drug Taxol, which is sold by Bristol-Myers Squibb (BMY:NYSE). Trading in Ivax was halted at 1:47 p.m. EDT with the stock last traded at $39.75, down $1.5. Bristol-Myers, meanwhile, was lately up 31 cents to $53.75. The two companies had tussled over Ivax's desire to introduce paclitaxel, the chemical name for Taxol. The drug is sold by Bristol-Myers for treatment of breast and ovarian cancer, and it has annual global sales of $1.5 billion. Large pharmaceutical companies have been waging war against drugmakers eager to produce generic versions of popular drugs. Eli Lilly (LLY:NYSE) earlier fought with Barr Laboratories (BRL:NYSE) over the latter's desire to produce a generic version of Prozac.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next